Tonix presents TNX-4800 Phase 1 data; plans adaptive Phase 2 field study for Lyme disease prevention in H1 2027

Tonix Pharmaceuticals Holding Corp.

Phase 1 data of TNX-4800 (anti-OspA mAb) for Lyme disease presented at Ticks and Tickborne Diseases Symposium.
Planned adaptive Phase 2 field study: two-dose SC regimen, primary endpoint 6-month protection; start H1 2027 pending FDA agreement.
FDA Type C meeting scheduled early Q3 2026 to discuss Phase 2 study design.
Each fixed subcutaneous dose expected to provide exposure comparable to 5 mg/kg dose in Phase 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.